R&D News | pharmaphorum

News

Pieris wields axe after losing AZ as partner for elarekibep

AstraZeneca has terminated a partnership with Pieris Pharmaceuticals on respiratory drug candidate elarekibep, forcing the latter to slash staff and look into its “strateg

News

Paul Biondi of Flagship's Pioneering Medicines

Pfizer inks $7bn strategic level R&D deal with Flagship

Pfizer has just made venture capital firm Flagship Pioneering a key component of its R&D engine, signing a deal worth up to $7 billion that will allow it to harvest ne

News

BridgeBio rebounds on ATTR cardiomyopathy data

BridgeBio is getting ready to file for FDA approval of its acoramidis drug for transthyretin amyloidosis (ATTR) cardiomyopathy, armed with positive results in a phase 3 tr

News

Donanemab data an “important advance” in Alzheimer’s

The full data from the TRAILBLAZER-ALZ 2 trial of Eli Lilly’s amyloid drug donanemab has confirmed the top-line results reported in May, but also

News

Alnylam showcases long-acting amyloid drug at AAIC

With the first amyloid-targeting drug now approved for Alzheimer’s disease, Alnylam has presented preliminary clinical results with a new candidate that could potentially

News

Lilly bulks up in obesity with $1.93bn Versanis buy

Already developing a trio of incretin drugs for obesity, Eli Lilly has its sights set on a candidate with a different mechanism of action that it hopes to acquire via a $1

Pieris wields axe after losing AZ as partner for elarekibep

Pfizer inks $7bn strategic level R&D deal with Flagship

BridgeBio rebounds on ATTR cardiomyopathy data

Donanemab data an “important advance” in Alzheimer’s

Alnylam showcases long-acting amyloid drug at AAIC

Lilly bulks up in obesity with $1.93bn Versanis buy

UK study finds clue to rising cancer rates in younger people

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks